Efficacy of alternate day versus daily dosing of rosuvastatin

Dulay, Daisy; LaHaye, Stephen A.; Lahey, Karen A.; Day, Andrew G.

doi:10.1016/s0828-282x(09)70480-5

Cited by 18 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Extended-interval dosing with rosuvastatin either as alternate day or various weekly administration regimens has been studied in small controlled or noncontrolled settings, enrolling fewer than 300 patients. 4–10…”

Section: Resultsmentioning

confidence: 99%

Rosuvastatin: Extended-Interval Dosing

Joyce

Dennis²

2011

Hosp Pharm

View full text Add to dashboard Cite

This Hospital Pharmacy feature is extracted from Off-Label Drug Pacts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Pacts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@kumc.edu .

show abstract

Section: Resultsmentioning

confidence: 99%

Rosuvastatin: Extended-Interval Dosing

Joyce

Dennis²

2011

Hosp Pharm

View full text Add to dashboard Cite

show abstract

“…On the other hand, the study by Dulay et al, where patients received double the daily dose of rosuvastatin on alternate days, demonstrated statistically significantly higher LDL-C levels compared with those in the daily group, though the clinical significance of the difference is questioned. 38 This result indicates that potency may not be an important factor in the lipid-lowering ability of alternate-day dosing.…”

Section: Discussionmentioning

confidence: 98%

“…38 Forty-five patients with an LDL-C greater than 135 mg/dL were randomly assigned to receive either rosuvastatin 10 mg daily or 20 mg every other day for 6 weeks (phase 1) after an initial 4-week washout period. After the first phase of the study, patients underwent a 4-week washout period and were then switched to the other regimen for another 6 weeks.…”

Section: Rosuvastatinmentioning

confidence: 99%

Alternate-Day Statin Therapy for the Treatment of Hyperlipidemia

2010

View full text Add to dashboard Cite

show abstract

“…4 Rosuvastatin every other day has been reported to lower LDL-C levels by 40.9% at a dose of 20 mg, by 39% at 10 mg and by 34% at a mean dose of 5.6 mg (range: 2.5-10 mg). 40,41 Additionally, atorvastatin every other day decreases LDL-C levels by 23% in comparison to 39% with daily dosing. With 20 mg of lovastatin every other day, LDL-C levels were reduced by 21% and the drug was tolerated by 98% of the studied subjects.…”

Section: Management Of Dyslipidaemiamentioning

confidence: 99%

Statin-Associated Muscle Adverse Events: Update for clinicians

Al-Mohaissen¹,

Ignaszewski²,

Fröhlich³

et al. 2016

SQUMJ

View full text Add to dashboard Cite

Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.

show abstract

Efficacy of alternate day versus daily dosing of rosuvastatin

Cited by 18 publications

References 23 publications

Rosuvastatin: Extended-Interval Dosing

Rosuvastatin: Extended-Interval Dosing

Alternate-Day Statin Therapy for the Treatment of Hyperlipidemia

Statin-Associated Muscle Adverse Events: Update for clinicians

Contact Info

Product

Resources

About